Endometrial Adenocarcinoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
E
Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +5 more
2022-01-10
Jan 10, 2022
M
Active, not recruiting
  • Endometrial Adenocarcinoma
  • Endometrial Carcinosarcoma
  • Basking Ridge, New Jersey
  • +6 more
2021-11-29
Nov 29, 2021
D
Active, not recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Mesa, Arizona
  • +5 more
2021-11-29
Nov 29, 2021
M
Recruiting
  • Endometrial Cancer
  • +8 more
  • Laparoscopic hysterectomy with sentinel lymph node biopsy
  • Istra, Moscow Region, Russian Federation
    Department of Gynecologic Oncology, Moscow City Oncology Hospita
2021-10-08
Oct 8, 2021
G
Active, not recruiting
  • Endometrial Adenocarcinoma
  • +11 more
  • Birmingham, Alabama
  • +430 more
2021-09-28
Sep 28, 2021
X
Completed
  • Endometrial Atypical Hyperplasia
  • Endometrial Adenocarcinoma
  • Megestrol acetate and metformin
  • Megestrol acetate
  • Shanghai, Shanghai, China
  • +4 more
2021-09-10
Sep 10, 2021
O
Active, not recruiting
  • Endometrial Adenocarcinoma
  • +3 more
  • Genetic Counseling
  • +3 more
  • Akron, Ohio
  • +8 more
2021-09-08
Sep 8, 2021
T
Recruiting
  • Carcinoma
  • +18 more
  • PEN-866 Sodium
  • +3 more
  • Springdale, Arkansas
  • +13 more
2021-07-13
Jul 13, 2021
S
Completed
  • Endometrial Hyperplasia
  • Endometrial Adenocarcinoma
  • routine stain by H&E.
  • Sohag, Egypt
    Maisa Hashem Mohammed
2021-05-05
May 5, 2021
A
Terminated
  • Endometrial Adenocarcinoma
  • +8 more
  • Bronx, New York
    Albert Einstein College of Medicine
2021-04-21
Apr 21, 2021
N
Completed
  • Endometrial Adenocarcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Hartford, Connecticut
  • +21 more
2020-10-13
Oct 13, 2020
M
Active, not recruiting
  • BRCA1 Mutation Carrier
  • +15 more
  • Houston, Texas
    M D Anderson Cancer Center
2020-07-17
Jul 17, 2020
M
Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
2020-07-17
Jul 17, 2020
F
Completed
  • Endometrial Adenocarcinoma
  • SLN mapping
  • Shanghai, China
    Obstetrics and Gynecology Hospital, Fudan University
2020-06-21
Jun 21, 2020
N
Completed
  • Endometrial Adenocarcinoma
  • +7 more
  • Sunitinib Malate
  • Beverly Hills, California
  • +28 more
2020-02-14
Feb 14, 2020
A
Completed
  • Endometrial Adenocarcinoma
  • Assuit, Egypt
    South Egypt Cancer instIitute
2020-01-19
Jan 19, 2020
N
Completed
  • Endometrial Adenocarcinoma
  • +4 more
  • Cediranib Maleate
  • Laboratory Biomarker Analysis
  • Burbank, California
  • +86 more
2019-08-06
Aug 6, 2019
N
Completed
  • Endometrial Adenocarcinoma
  • +4 more
  • Laboratory Biomarker Analysis
  • Trastuzumab
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
2019-07-30
Jul 30, 2019
N
Completed
  • Endometrial Adenocarcinoma
  • +2 more
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
2019-07-22
Jul 22, 2019
N
Completed
  • Endometrial Adenocarcinoma
  • +3 more
  • Los Angeles, California
  • +71 more
2019-07-19
Jul 19, 2019
U
Withdrawn
  • Endometrial Cancer
  • +3 more
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
2019-06-25
Jun 25, 2019
N
Completed
  • Endometrial Adenocarcinoma
  • +15 more
  • Houston, Texas
    M D Anderson Cancer Center
2018-04-04
Apr 4, 2018
G
Completed
  • Endometrial Adenocarcinoma
  • +8 more
  • Dalantercept
  • Laboratory Biomarker Analysis
  • San Francisco, California
  • +29 more
2018-02-13
Feb 13, 2018